Table of Contents
Overview
New York, NY – April 02, 2025 – Global Nasal Cannula Market size is expected to be worth around USD 14.6 Billion by 2033, from USD 7.9 Billion in 2023, growing at a CAGR of 6.3% during the forecast period from 2024 to 2033.
The global nasal cannula market is experiencing steady growth, driven by increasing cases of respiratory disorders such as chronic obstructive pulmonary disease (COPD), asthma, and pneumonia. The rising prevalence of hypoxemia and the growing geriatric population have further fueled the demand for oxygen therapy devices, including nasal cannulas.
Technological advancements, such as high-flow nasal cannulas (HFNC) with improved humidification systems, are enhancing patient comfort and treatment efficiency. The market is also benefiting from the expansion of home healthcare services, which provide cost-effective solutions for long-term oxygen therapy.
North America dominates the global market due to advanced healthcare infrastructure and a high incidence of respiratory diseases. However, Asia-Pacific is expected to witness the fastest growth, driven by rising healthcare expenditures, increasing pollution-related respiratory conditions, and growing awareness of oxygen therapy.
Key industry players are focusing on product innovations, strategic partnerships, and mergers & acquisitions to strengthen their market position. The demand for disposable nasal cannulas is also increasing, given the emphasis on infection control. As respiratory illnesses continue to rise globally, the nasal cannula market is expected to grow steadily, with significant opportunities in both hospital and homecare settings.
Key Takeaways
- The Global Nasal Cannula Market is anticipated to reach approximately USD 14.6 billion by 2033.
- In 2023, the market size for Nasal Cannulas was valued at USD 7.9 billion.
- The market is projected to grow at a Compound Annual Growth Rate (CAGR) of 6.3% from 2023 to 2033.
- Chronic respiratory diseases account for approximately 41% of increased morbidity, with asthma and COPD being the primary contributors.
- In 2023, Low Flow Nasal Cannulas dominated the market, capturing over 65% of the market share.
- Plastic nasal cannulas accounted for more than 85.3% of the market share in 2023 due to their cost-effectiveness.
- Hospitals held a dominant market position in 2023, with a market share exceeding 44.9%.
- North America led the market in 2023 with a 42.3% share, driven by the increasing prevalence of respiratory diseases.
Segmentation Analysis
Type Analysis: In 2023, the Low Flow Nasal Cannula segment led the market with over a 65% share, driven by its widespread use for patients requiring minimal oxygen support. These cannulas are cost-effective, easy to use, and suitable for diverse patient groups. Meanwhile, the High Flow Nasal Cannula segment is growing rapidly due to its ability to deliver up to 60 liters of heated, humidified oxygen per minute, making it ideal for acute care settings like ICUs and emergency departments.
Material Analysis: Plastic nasal cannulas dominated the market in 2023 with an 85.3% share, attributed to their affordability and widespread availability in various healthcare settings. They are lightweight and suitable for short-term oxygen therapy. Silicone nasal cannulas, though smaller in market share, are gaining traction due to their superior comfort, flexibility, and durability. They are preferred for long-term oxygen therapy, especially among chronic respiratory patients, despite their higher cost.
End-use Analysis: Hospitals accounted for over 44.9% of the nasal cannula market in 2023, driven by the high demand for oxygen therapy in acute care and post-operative settings. Ambulatory healthcare services, including outpatient centers, are witnessing increased adoption due to their cost efficiency. Long-term care centers also play a key role, catering to chronic respiratory patients requiring continuous oxygen therapy. The home healthcare segment is growing due to the rising preference for at-home treatment, especially among the aging population.
Market Segments
Based On Type
- Low Flow Nasal Cannula
- High Flow Nasal Cannula
Based On Material
- Plastic
- Silicone
Based On End-use
- Hospitals
- Ambulatory Healthcare Services
- Long-Term Care Centers
- Others
Regional Analysis
In 2023, North America dominated the nasal cannula market, capturing a 42.3% share, valued at USD 3.3 million. This leadership is driven by the increasing prevalence of respiratory diseases such as COPD and asthma, which account for nearly 80% of chronic disease-related healthcare expenditures in the region. The strong presence of both local and international manufacturers has enhanced the accessibility and affordability of advanced nasal cannulas, further accelerating market growth.
Notably, in 2022, the U.S. alone generated over USD 2.9 billion in nasal cannula market revenue. A key development in this space was the launch of Luisa by Movair in October 2021, an advanced ventilator capable of switching between high-flow nasal cannula (HFNC) and non-invasive ventilation modes.
Meanwhile, Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by the rising incidence of asthma and COPD, an aging population, and increasing healthcare expenditures. Additionally, the expansion of local manufacturers is further contributing to the region’s market growth, making nasal cannula solutions more accessible to a broader patient base.
Emerging Trends
Advancements in High-Flow Nasal Cannula (HFNC) Therapy
Innovations in HFNC technology have enhanced oxygen delivery efficiency, particularly benefiting patients with respiratory conditions. Recent studies have demonstrated that HFNC therapy, when used as early respiratory support in children under five years with acute hypoxemic respiratory failure due to severe community-acquired pneumonia, is associated with significantly lower treatment failure compared to standard low-flow oxygen support.
Increased Adoption in Pediatric Care
The utilization of HFNC in pediatric settings has seen a significant rise. For instance, a study in Italy reported that 66% of children admitted for bronchiolitis received HFNC during the latest season onset period, compared to 35–38% in pre-pandemic periods. This increase suggests a growing confidence among healthcare providers in the efficacy of HFNC for managing pediatric respiratory conditions.
Integration with Nebulized Therapies
The development of nebulizer adapters compatible with HFNC systems represents a significant advancement. These adapters facilitate the simultaneous delivery of aerosolized medications and humidified oxygen, enhancing patient care, especially for those requiring combined therapies.
Innovative Modifications for Enhanced Oxygenation
Researchers have proposed simple yet effective modifications to standard nasal cannulas to increase the concentration of inhaled oxygen. By incorporating reservoirs that reduce room air dilution, these adaptations aim to improve oxygen delivery efficiency, particularly in critical care settings.
Challenges in Humidification Performance
Studies have highlighted variations in humidification performance among different HFNC devices. Factors such as flow rate, device type, and interface design significantly impact the temperature and humidity of delivered gases. Understanding these differences is crucial for optimizing patient comfort and therapeutic efficacy.
Use Cases
- Management of Acute Hypoxemic Respiratory Failure (AHRF) in COVID-19 Patients: During the COVID-19 pandemic, HFNC has been instrumental in treating patients with AHRF. A retrospective study reported a 48.2% success rate in avoiding mechanical ventilation among critically ill COVID-19 patients treated with HFNC.
- Pediatric Asthma Treatment: In pediatric patients with severe asthma exacerbations, HFNC has been employed to alleviate respiratory distress. However, its use has been associated with increased hospital length of stay, indicating the need for careful patient selection and monitoring
- Preventing Invasive Ventilation: HFNC serves as a non-invasive alternative to mechanical ventilation in various settings. Its application has been linked to reduced progression to invasive ventilation and mortality in patients with acute respiratory conditions.
Conclusion
The nasal cannula market is poised for sustained growth, driven by rising respiratory diseases, technological advancements, and increasing demand for home-based oxygen therapy. High-flow nasal cannulas (HFNC) are gaining traction due to their superior oxygen delivery efficiency, especially in critical care and pediatric settings. North America leads the market, while Asia-Pacific is projected to witness the fastest expansion.
The integration of nebulized therapies and innovations in humidification are enhancing patient outcomes. As healthcare providers prioritize infection control and comfort, disposable and silicone-based nasal cannulas are gaining popularity. Overall, the market offers significant opportunities in both hospital and homecare environments.
Discuss your needs with our analyst
Please share your requirements with more details so our analyst can check if they can solve your problem(s)
